Top 13 Biotech Companies in India 2022

Here we can see the List of Top Biotech Companies in India. India’s biotechnology sector has evolved steadily over the last two decades, placing the country among the top 12 biotechnology destinations in the world.

Top 10 Pharmaceuticals Companies in India

Biotechnology Companies

So here is the List of Biotechnology Companies in India which is arranged in alphabetical order.

• ADINATH BIO-LABS LTD.
• ALPA LABORATORIES LTD.
• BIOCON LTD.
• Camson Bio Technologies Ltd
• Camson Bio Technologies Ltd
• Celestial Biolabs Limited
• Genesis Ibrc India Ltd
• Genomic Valley Biotech Ltd
• MAVENS BIOTECH LTD.
• PANACEA BIOTEC LTD.
• SAAMYA BIOTECH (INDIA) LTD.
• Shree Ganesh Biotech (India) Ltd
• VIVO BIO TECH LTD.

List of Biotech Companies in India

So here is the list of Biotechnology Companies in India with company code and ISIN NO. The list of companies was arranged in the Alphabetical Order.

S NO	Companies Name	Security Code	Security Id	Face Value	ISIN No
1	ADINATH BIO-LABS LTD.	590088	ADINATHBI	1	INE129D01039
2	ALPA LABORATORIES LTD.	532878	ALPA	10	INE385I01010
3	BIOCON LTD.	532523	BIOCON	5	INE376G01013
4	Camson Bio Technologies  Ltd-$	590076	CAMSONBIO2	10	INE845E01012
5	Camson Bio Technologies Ltd	538858	CAMSONBIO	10	INE845E01012
6	Celestial Biolabs Limited	532871	CELESTIAL	10	INE221I01017
7	Genesis Ibrc India Ltd	514336	GENESIS	10	INE194N01016
8	Genomic Valley Biotech Ltd	539206	GVBL	10	INE574D01010
9	MAVENS BIOTECH LTD.	590083	MAVENSBIO	1	INE856C01047
10	PANACEA BIOTEC LTD.	531349	PANACEABIO	1	INE922B01023
11	SAAMYA BIOTECH (INDIA) LTD.	532905	SAAMYABIO	10	INE320H01019
12	Shree Ganesh Biotech (India) Ltd	539470	SHREEGANES	10	INE051N01018
13	VIVO BIO TECH LTD.	511509	VIVOBIOT	10	INE380K01017

List of Pharma Company in India

Largest Biotechnology Company In India

Biocon Limited is the Largest Biotechnology Companies in India which has turnover of Rs 6315 Cr.

1. Biocon Limited

Biocon Limited (“Biocon” or “the Company”), is engaged in the manufacture of biotechnology products and research services.

• Revenue: Rs 6315 Cr
• Market Cap:  42,329 Cr.
• ROE: 12.86 %
• Sales Growth (3Yrs): 18.10 %

The Company is a public limited company incorporated and domiciled in India and has its registered in Bengaluru, Karnataka, India. The Company’s shares are listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) in India.

2. Serum Institute of India Pvt. Ltd

Serum Institute of India is ranked as India’s No. 1 biotechnology company, manufacturing highly specialized life saving biologicals like vaccines using cutting edge genetic and cell based technologies, antisera and other medical specialties.

Serum Institute of India Pvt. Ltd. is now the world’s largest vaccine manufacturer by number of doses produced and sold globally (more than 1.5 billion doses) which includes Polio vaccine as well as Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps and Rubella vaccines.

It is estimated that about 65% of the children in the world receive at least one vaccine manufactured by Serum Institute. Vaccines manufactured by the Serum Institute are accredited by the World Health Organization, Geneva and are being used in around 170 countries across the globe in their national immunization programs, saving millions of lives throughout the world.

• Revenue: Rs 5,900 Cr
• more than 1.5 billion doses
• 65% of the children in the world receive at least one vaccine manufactured by Serum Institute.

Serum Institute of India was founded in 1966 by Dr. Cyrus Poonawalla with the aim of manufacturing life-saving immuno-biologicals, which were in shortage in the country and imported at high prices. Thereafter, several life-saving biologicals were manufactured at prices affordable to the common man and in abundance, with the result that the country was made self-sufficient for Tetanus Anti-toxin and Anti-snake Venom serum, followed by DTP (Diphtheria, Tetanus and Pertussis) group of Vaccines and then later on MMR (Measles, Mumps and Rubella) group of vaccines.

The Philanthropic philosophy of the company still not only exists but has been proliferated to bring down the prices of newer vaccines such as Hepatitis-B vaccine, Combination vaccine etc., so that not only Indian’s, but the entire under-privileged children of the world are protected from birth onwards.

3. Panacea Biotec Ltd

Panacea Biotec is an Innovation driven Biotechnology company doing Research and Development, Manufacturing, Sales, Distribution and Marketing of Pharmaceuticals, Vaccines and Biosimilars.

Panacea Biotec was set up in the year 1984, under the name of Panacea Drugs Private  Limited with a commitment to make Innovative Products Affordable and Accessible to the masses. It got publically listed on Indian National Stock Exchanges in September 1995 as Panacea Biotec Ltd.

Panacea Biotec is witnessing a period of expansion across every aspect of our business from innovative products to customers in market, from manufacturing to regulatory approvals and thereby laying the foundation for translation of our vision in becoming greatest, largest and most admired biotechnology company in the World by 2020.

• Total Sales: Rs 544 Cr
• Market Cap: ₹ 1,165 Cr.
• ROCE: 1.30 %
• ROE: -67.6 %
• Face Value: ₹ 1.00
• Promoter holding: 73.6 %
• Debt to equity: 3.10
• Price to book value: 5.87
• EVEBITDA: 30.8
• Price to Sales: 2.14

Ardent Research and Development efforts have always been a great strength of Panacea Biotec. The main research areas are New Chemical Entities (NCE), New Biological Entities (NBE) Novel Drug Delivery System (NDDS) based pharmaceutical formulations, Novel peptides & human monoclonal antibodies and Vaccine development.

The company has developed four distinguished, ultra-modern, state-of-art R&D centres in different locations, having internal capabilities for constant research, with over 300 highly professional and skilled scientists engaged in various aspects of research.

Focused research efforts have led to grant of worldwide product patents valid in over 68 countries for Panacea Biotec. As on 31st March 2011, the company had filed over 1400 patent applications in various parts of the world including India. Of these, 382 have been granted patent and others are under various stages of examination or publication by the patent authorities.

Some of these countries are USA, U.K., France, Germany, Italy, Sweden, Denmark, Spain, Finland, Switzerland, The Netherlands, New Zealand, Mexico, Brazil, Nigeria, Zimbabwe, Australia, South Africa, Japan, Russia, Canada, Ukraine, Korea, and China.

The Company aspirations are supported by our Globally accredited USFDA approved manufacturing facility at Baddi supported by the 4 “State-of-the-Art” R&D Centres.

The company has ultra-modern, state-of-art production facilities at Baddi (Himachal Pradesh), Lalru (Punjab) & Delhi for manufacturing tablets, capsules (including soft gelatin), ointments (including transgel formulation) liquids, herbal formulations and vaccines. The facilities are WHO cGMP compliant among other regulatory bodies such as USFDA, UKMHRA, Saudi FDA, ANVISA, etc.

The product portfolio includes highly innovative prescription products in niche therapeutic areas such as Pain Management, Diabetes & Cardiovascular management, Oncology, Renal Disease management, Osteoporosis management, Anti-tubercular, Gastro-intestinal care products and Vaccines.

The Company current business stems from our leadership segments in India i.e. Transplant, Nephrology, Diabetes & Pain with some exclusive products based on patented Drug Delivery Systems.

First Nanotechnology based product ‘PacliAll’ (Paclitaxel in protein bound particles) was launched in 2011; it was the world’s first generic for Abraxane, manufactured by Celegene USA. Apart from fortifying our presence in the above segments; we are planning major forays in Gastrointestinal, Osteoporosis, Cardiovascular & more importantly Oncology.

Panacea Biotec is one of the largest Vaccine Manufacturing Company in India and is well acknowledged by the UN Health Agencies in partnering the Polio eradication initiative with supplies of millions of doses of WHO Pre-qualified Polio vaccine. As a sequel to the completion of full range of Oral polio vaccines (tOPV, mOPV1, mOPV3 & bOPV).

Panacea Biotec has introduced the next generation Inactivated Polio vaccine (eIPV) vide a collaboration with the Netherland Vaccine Institute (NVI). This vaccine has found extensive usage in India for more than 3 years now and is registered in Bangladesh. IPV is also in advanced stage of registration in 10 countries word wide with the target of being in more than 30 countries in a couple of years and has been put up for WHO prequalification which is expected soon.

Panacea Biotec is the first company in to have developed fully liquid Pentavalent vaccine (DTwP+Hep B+Hib) Easy Five in 2005. Easy Five is a WHO Prequalified vaccine being used in more than 25 countries worldwide.

The vaccines portfolio consists of Enivac-HB (Hepatitis B vaccine), Enivac-HB Safsy, Ecovac-4 (DTwP+Hep B), Easyfour (DTwP+Hib), which are also WHO prequalified. Vaccines in the offing are- Anthrax, Dengue, Japanese encephalitis and several others. A strong innovative vaccine pipeline is on the anvil which would pave the way for a consistent introduction of Next Generation Vaccines in future.

Panacea Biotec is the third largest biotechnology company (as per ABLE Survey, 2011), as well as among the top 50 pharmaceutical companies (as per ORG IMS March 2010) of India. To tap newer opportunities, Panacea Biotec has organized its formulation marketing into Six SBUs – PRO Care, Diacar Alpha, Diacar Delta, GROW Care, Onco Trust, and Critical Care, which enables it to respond to changes in the industry and marketplace.

The Company has tied up with National Institute of Immunology, India for Japanese Encephalitis candidate vaccine, Biotech Consortium India Ltd. for the development, manufacture and marketing of Anthrax vaccine, worldwide and with National Institute of Health, USA, for use of a peptide-based product for generation of hair follicles and hair growth.

Panacea Biotec has also collaborated with Netherlands Vaccine Institute for Inactivated Polio Vaccine; NRDC- India for Foot & Mouth Disease vaccine for veterinary use and Bio Farma-Indonesia for Measles vaccine. Panacea Biotec has established a countrywide sales and marketing network in India through a vibrant sales force of more than 1,500 professionally trained and highly motivated marketing and sales professionals and efficient logistic network of 22 sales depots/carrying and forwarding agents all over India to make its products available at all places and at all times.

While Panacea Biotec Ltd has achieved a plethora of credentials on Home ground (India); it has also consolidated its presence in about 21 markets across CIS, Latin America, Middle East, Asia & Africa.

The Company International Pharma business performance for the current financial year is pegged at nearly US $ 16 million with a robust growth of nearly 150%. The financials are expected to improve in a similar exponential manner in the next 2-3 years due to expected commercialization in Key markets across US, Latin America & Europe.

Panacea Biotec has identified brand building in exports as its thrust area and it has significant presence in the global markets including the CIS, Africa, the Middle East and Asia. The company is actively exploring opportunities for launching as well as licensing out some of our patented products for manufacture/marketing in developed countries in Europe & North America.